Home・Akciju saraksts・Eli Lilly and Co.

Eli Lilly and Co.

Slēgts

SektorsVeselības aprūpe

1,184.33 -0.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1179.31

Max

1187.42

Galvenie mērījumi
By Trading Economics
Ienākumi	758M 7.4B
Pārdošana	507M 20B
P/E Sektora vidējais	39.835 68.51
EPS	8.55
Dividenžu ienesīgums	0.54
Peļņas marža	37.355
Darbinieki	50,000
EBITDA	1.3B 9.7B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+16.03% upside

Dividendes
By Acuity
Dividenžu ienesīgums Sektora vidējais	0.54% 2.29%
Nākamie ieņēmumi	2026. g. 29. okt.
Nākamais dividenžu datums	2026. g. 10. sept.
Nākamais Ex dividenžu datums	2026. g. 14. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	249B 1T
Iepriekšējā atvēršanas cena	1184.96
Iepriekšējā slēgšanas cena	1184.33

Eli Lilly and Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. aug. 00:02 UTC

News

Eli Lilly shares are higher in after-market trading following FDA filing plans for retatrutide, a potential competitor in the weight-loss market.

2026. g. 7. aug. 19:16 UTC

News

Social Media

Eli Lilly shares are lower today, despite an increase in TRx sales to 34,219 from 29,388 last week. The stock remains within its one-month range.

2026. g. 6. aug. 19:16 UTC

Social Media

News

Eli Lilly shares rose as analysts raised price targets, reflecting strong quarterly results and demand growth for its obesity drugs.

2026. g. 5. aug. 23:42 UTC

News

Eli Lilly reported second-quarter revenue of $23 billion, raising its full-year guidance to $85 billion to $87 billion. Shares are higher in after-market trading.

2026. g. 4. aug. 23:02 UTC

Eli Lilly shares are higher in after-market trading, driven by a broader market rally and optimism surrounding potential oil supply agreements.

2026. g. 3. aug. 20:03 UTC

News

Social Media

Event

Eli Lilly's shares are declining amid negative sentiment despite expanding access to its obesity drug retatrutide and receiving FDA designation for olomorasib.

2026. g. 31. jūl. 23:06 UTC

Eli Lilly and Co shares are higher in after-market trading, though they remain below their 20-day moving average by 2.91%. No specific news was identified.

2026. g. 30. jūl. 21:01 UTC

Eli Lilly shares are higher in after-market trading, recovering from an earlier dip. Broader market sentiment remains positive amid geopolitical tensions and inflation concerns.

2026. g. 29. jūl. 23:26 UTC

Eli Lilly and Co shares are lower in after-market hours amid unusual trading activity. Broader market volatility follows the Federal Reserve's interest rate decision.

2026. g. 28. jūl. 22:06 UTC

Eli Lilly shares are lower in after-market hours, with no specific news identified. Broader market trends may be impacting sentiment following declines in the Nikkei 225 Index.

2026. g. 27. jūl. 23:16 UTC

Eli Lilly and Co shares are lower in after-market hours, continuing a decline since Monday's close amid a broader market downturn. No specific news was identified.

2026. g. 24. jūl. 23:41 UTC

Eli Lilly and Co shares declined in after-market trading, experiencing notable fluctuations without any specific news to explain the price action.

2026. g. 23. jūl. 10:06 UTC

Social Media

Eli Lilly shares are lower in pre-market trading, nearing the $1074–$1003 support zone. Broader market declines coincide with traders awaiting the ECB's interest rate decision.

2026. g. 22. jūl. 23:16 UTC

Social Media

Eli Lilly acquires ATAI for $2.8 billion, entering the psychedelic medicine sector. Shares are higher in after-market trading following the announcement.

2026. g. 21. jūl. 20:07 UTC

Social Media

News

Eli Lilly is higher today, supported by overall market strength and plans to defend against a lawsuit from Novo Nordisk over its weight-loss drugs.

2026. g. 20. jūl. 23:16 UTC

Eli Lilly's shares are roughly flat in after-market trading, amid rising treasury yields and geopolitical tensions affecting interest-sensitive sectors like pharmaceuticals.

Salīdzinājums

Cenas izmaiņa

Eli Lilly and Co. Prognoze

Cenas mērķis

By TipRanks

16.03% augšup

Prognoze 12 mēnešiem

Vidējais 1,375.78 USD 16.03%

Augstākais 1,600 USD

Zemākais 1,135 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

20 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 20 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.